Antimicrobial Agents and Chemotherapy

Biography

Angel G Martin obtained his PhD in 1999 at the Universidad Autonoma de Madrid (Spain) and the Centro de Biología Molecular Severo Ochoa, focused on transcriptional regulation of T cell activation by citokines. In 2000 he moved to the National Cancer Institute at Frederick (NIH; USA) for Postdoctoral training in oncogene-induced apoptosis. He returned to Spain in 2005 as investigator for the genomic regulation of cancer group at Centro de Investigación Príncipe Felipe, Valencia. In 2006 he moved to the Bilbao area to work as a senior researcher at Proteomika SL. In March 2007 he joined Inbiomed to start the Regulation of Cell Growth Laboratory. His main research interest is to understand the role of stem cells in cancer through characterization of cancer initiating cells in order to find novel therapeutic and diagnostic/prognostic targets. Later that year he also became Director of Inbiobank, the biorepository of Fundacion Inbiomed dedicated to adult stem cell banking. In July 2013 he co-founded StemTek Therapeutics, a start-up biotech company dedicated to finding new drugs for cancer treatment based on understanding the biology of cancer stem cells and since then he is exclusively dedicated to StemTek Therapeutics serving as CSO and member of the Board. He has published more than 40 papers in reputed journals and has been serving as an editorial board member of repute.

Abstract

Abstract : Drug development targeting cancer stem cells